Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

AVI BioPharma Announces Second Quarter Financial Results Conference Call.


Business Editors/Health/Medical Writers

PORTLAND, Ore.--(BUSINESS WIRE)--July 24, 2003

AVI BioPharma Inc. (Nasdaq:AVII) (Nasdaq:AVIIW) (Nasdaq:AVIIZ) today announced that the Company will hold a conference call to discuss 2003 second quarter financial results on Tuesday, August 5, 2003, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).

The conference call can be heard live via audio webcast at the Company's Web site: www.avibio.com. A replay will also be available for 14 days.

A telephone replay of the conference call will be available for 48 hours beginning August 5 at approximately 12:00 p.m. Eastern Time by dialing 800-642-1687 domestically, or 706-645-9291 Internationally and entering reservation number 1874784.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third-generation NEUGENE antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid).  drugs and cancer immunotherapy. AVI's lead NEUGENE antisense compound is designed to target cardiovascular restenosis, cancer, polycystic kidney disease Polycystic Kidney Disease Definition

Polycystic kidney disease (PKD) is one of the most common of all life-threatening human genetic disorders.
 and other cell proliferation disorders. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to target single-stranded RNA viruses RNA viruses,
n See viruses.
, including West Nile virus West Nile virus, microorganism and the infection resulting from it, which typically produces no symptoms or a flulike condition. The virus is a flavivirus and is related to a number of viruses that cause encephalitis. , SARS coronavirus, calicivirus, and Hepatitis C. AVI's second technology, AVICINE(R), is a therapeutic cancer vaccine with late-stage trials planned for the treatment of pancreatic and colorectal cancer. More information about AVI (Audio Video Interleaved) A Windows multimedia video format from Microsoft. It interleaves standard waveform audio and digital video frames (bitmaps) to provide reduced animation at 15 fps at 160x120x8 resolution. Audio is 11,025Hz, 8-bit samples.  is available on the company's Web site at http://www.avibio.com/.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's Securities and Exchange Commission filings.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 24, 2003
Words:316
Previous Article:Zapf Creation Boosts Profitability.
Next Article:S&PBULLETIN: L&G Reports Unchanged H1 2003 Op Profits.
Topics:



Related Articles
AVI BioPharma Announces Third Quarter Financial Results Conference Call.
AVI BioPharma Announces 2003 Fourth Quarter and Year-End Financial Results Conference Call.
AVI BioPharma Announces 2004 First Quarter Financial Results Conference Call.
AVI BioPharma Announces 2004 Second Quarter Financial Results Conference Call.
Oregon firm tests West Nile drug.
AVI BioPharma Announces 2004 Third Quarter Financial Results Conference Call.
AVI BioPharma Announces 2005 Second Quarter Financial Results Conference Call.
AVI BioPharma Reports Second Quarter Financial Results; Conference Call Begins Today at 11:00 a.m. Eastern Time.
AVI BioPharma Reports Second Quarter Financial Results; Conference Call Begins Today at 11:00 a.m. Eastern Time.
AVI BioPharma Announces 2007 First Quarter Financial Results Conference Call.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles